Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648135 | 0.84 | POLB (0.54) | POLBMAPTGAAHCAR2HTT | |
| SCHEMBL12648330 | 0.83 | POLB (0.52) | POLBMAPTGAAHCAR2HTT | |
| SCHEMBL12648341 | 0.81 | POLB (0.54) | POLBMAPTGAAHCAR2HTT | |
| SCHEMBL11170815 | 0.73 | MAPT (0.50) | POLBMAPTGAATSHRSMN1; SMN2 | |
| SCHEMBL1520716 | 0.72 | POLB (1.00) | POLBMAPTGAAHCAR2HTT | |
| SCHEMBL1781122 | 0.72 | MAPT (0.57) | POLBMAPTGAAHCAR2HTT | |
| Acetic Acid SCHEMBL11173187 | 0.71 | BRD4 (0.47) | POLBMAPTGAAHCAR2HTT | |
| SCHEMBL657849 | 0.70 | POLB (0.56) | POLBMAPTGAAHCAR2HTT | |
| SCHEMBL1554818 | 0.70 | POLB (0.50) | POLBMAPTGAAHCAR2TSHR | |
| SCHEMBL22111733 | 0.69 | POLB (0.54) | POLBMAPTGAAHCAR2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846747-B2 | Compounds and methods for altering lifespan of eukaryotic organisms | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | claimed |
| US-8846747-B2 | Compounds and methods for altering lifespan of eukaryotic organisms | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846747-B2 | Compounds and methods for altering lifespan of eukaryotic organisms | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| US-8592430-B2 | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SLR (IT) | 2013-11-26 | — | — | US | disclosed |
| US-20130096175-A1 | Compounds and Methods for Altering Lifespan of Eukaryotic Organisms | SOUTHERN RESEARCH INSTITUTE (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096175-A1 | Compounds and Methods for Altering Lifespan of Eukaryotic Organisms | SOUTHERN RESEARCH INSTITUTE (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011062964-A1 | COMPOUNDS AND METHODS FOR ALTERING LIFESPAN OF EUKARYOTIC ORGANISMS | UNIVERSITY OF ROCHESTER (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| EP-2144889-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC S.r.l. (IT) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | POLB 1554/4885MAPT 296/4885GAA 1626/4885 |
| US-20130096175-A1 | Compounds and Methods for Altering Lifespan of Eukaryotic Organisms | HDAC5, AADAC, SIRT1 | POLB 2377/4885MAPT 2167/4885GAA 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.